---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-005542"
form_type: "8-K"
ticker: "PMDI"
cik: "0000806517"
company_name: "PSYCHEMEDICS CORP"
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:26:30.719337+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Psychemedics Q2 2022 revenue up 7% to $6.5M; net loss $0.3M vs net income $0.1M YoY

## Summary
- Revenue $6.5M for Q2 2022, up 7% from $6.1M in Q2 2021; domestic revenue up 13% but Brazil down 65%.
- Net loss of $0.3M ($0.06 diluted EPS) vs net income of $0.1M ($0.02 EPS) YoY; prior-year quarter had $0.8M ERC benefit.
- Declared quarterly dividend of $0.07/share, payable Sept 9, 2022 to holders of record Aug 24, 2022.
- Cash $1.8M and working capital $5.6M as of June 30, 2022; equipment financing down to $0.9M from $12.2M borrowed.
- Continuing review of strategic alternatives; no assurance of any transaction or outcome.

## SEC filing metadata
- accession: 0001171843-22-005542
- form_type: 8-K
- ticker: PMDI
- cik: 0000806517
- company_name: PSYCHEMEDICS CORP
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/806517/000117184322005542/0001171843-22-005542-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/806517/000117184322005542/f8k_080922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-005542
- JSON: https://secwatch.observer/filing/0001171843-22-005542.json
- Plain text: https://secwatch.observer/filing/0001171843-22-005542.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.